Iwona Danielewicz

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma

Martin Hutchings, Lale Kostakoğlu, Jan Maciej Zaucha et al. · Journal of Clinical Oncology · 2014 · 88 citations · Full text

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Eric Van Cutsem, Iwona Danielewicz, Mark Saunders et al. · Annals of Oncology · 2020 · 58 citations · Full text

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Loretta J. Nastoupil, Miguel Arturo Pavlovsky, Iwona Danielewicz et al. · Blood Advances · 2023 · 22 citations · Full text

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Eric Van Cutsem, Iwona Danielewicz, Mark Saunders et al. · British Journal of Cancer · 2022 · 16 citations · Full text